Rupafin: second-generation antihistamine

Rupafin (rupatadine) has launched for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents.

Rupatadine is a second-generation antihistamine with selective peripheral H1-receptor antagonist activity.

Desloratadine, one of the metabolites of rupatadine, may partially contribute to the overall efficacy of the drug.

The recommended dose of Rupafin in adults is one 10mg tablet daily, taken with or without food. Rupafin is not recommended for use in children under 12 years or patients with renal or hepatic impairment. It should be used with caution in elderly patients.

View Rupafin drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...